

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 6998)

CHANGE OF DATE OF BOARD MEETING

Reference is made to the announcement of Genor Biopharma Holdings Limited (the “**Company**”) dated 13 August 2025 in relation to the meeting of the board of directors of the Company (the “**Board**”) to be held on Wednesday, 27 August 2025 for the purpose of considering and approving, among other matters, the interim results of the Company and its subsidiaries for the six months ended 30 June 2025 and its publication.

The Board hereby announces that the abovementioned Board meeting has been rescheduled to be held on 29 August 2025 (Friday).

By order of the Board
Genor Biopharma Holdings Limited
Mr. Weng Chengyi
Executive Director and Chief Financial Officer

Hong Kong, 27 August 2025

As at the date of this announcement, the Board comprises six (6) Directors, namely Mr. WENG Chengyi (Chief Financial Officer) as an executive Director; Mr. YU Tieming and Mr. LIU Yi as non-executive Directors; and Ms. CUI Bai, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive Directors.